Syndivia

Syndivia develops advanced antibody-drug conjugates (ADCs) using proprietary platforms like GeminiMab™ and DAR1™, focusing on enhancing therapeutic efficacy for oncology treatments through innovative drug conjugation techniques. Founded in 2014 in Illkirch-Graffenstaden, France, Syndivia specializes in the design and development of antibody-drug conjugates. The company's leadership includes CEO Sasha Koniev. Syndivia has successfully completed three funding deals, with the most recent in August 2022, raising EUR 750,000 led by Cap Innov'Est.

The company has achieved a total amount raised of EUR 750,000 and currently holds a valuation of EUR 5. 408 mn. Syndivia specializes in developing advanced antibody-drug conjugates (ADCs), leveraging its proprietary GeminiMab™ and DAR1™ platforms to enhance therapeutic efficacy. The company focuses on optimizing the drug-to-antibody ratio (DAR), crucial for improving cancer treatment outcomes.

Syndivia primarily serves biopharmaceutical firms and research institutions in oncology, providing products aimed at improving precision and effectiveness in cancer therapies across global markets, notably in North America and Europe. In the most recent financial year of 2023, Syndivia reported a revenue of EUR 171,143. 90 with an EBITDA of EUR -236,743. 50.

The revenue model is driven by partnerships with biopharmaceutical companies that utilize its ADC technologies, primarily through exclusive licensing agreements and collaborative research partnerships, facilitating a B2B model that integrates Syndivia’s technologies into clients’ product pipelines. Syndivia plans to leverage the EUR 750,000 raised in August 2022 to support the development of new ADC products aimed at enhancing treatment options in oncology. The company is targeting expansion into North America and Europe by the end of 2024 to increase its market footprint. The funding will assist in scaling operations and advancing product development initiatives.